Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma

drug protocol number
MO22923
drug sponsor
Roche
drug study
Bevacizumab
drug trial site
KFMC
drug status
Completed
drug phase